Daewoong Pharmaceutical Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Daewoong Pharmaceutical Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Daewoong Pharmaceutical Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Daewoong Pharmaceutical Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Daewoong Pharmaceutical Co Ltd (Daewoong Pharmaceutical), a subsidiary of Daewoong Co Ltd, manufactures and distributes prescription drugs, quasi drugs, healthcare products, and APIs. It offers biologics, small‑molecule chemicals, over-the-counter (OTC) products, medical devices, and products for conditions such as bone and joint diseases, cardiovascular diseases, central nervous system disorders, dermatological conditions, gastrointestinal disorders, respiratory conditions, wound care, endocrinology, nephrology, obesity, and antivirals. The company's major products include NABOTA botulinum toxin type A, CareTropin somatropin, Eposis rhEPO, Easyef rhEGF, Fexuclue, ENVLO, V-OLET, Luphere Depot, Olostar, URSA, and COVID-19 diagnostic and transport devices. The company operates in Japan, the US, Canada, Switzerland, Germany, Indonesia, China, Vietnam, Israel, Thailand, and India. Daewoong Pharmaceutical is headquartered in Seoul, South Korea.
Headquarters
South Korea
Address
35-14, Jeyakgongdan 4-Gil, Hyangnam-Eup, Hwaseong, 18623
Website
www.daewoong.co.kr
Telephone
82 25508800
No of Employees
1,742
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
069620 (KRX)
Revenue (2024)
$1.1B
10.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
691.8%
(2024 vs 2023)
Market Cap*
$964.4M
Net Profit Margin (2024)
XYZ
616.7%
(2024 vs 2023)
* As of and is in US$
Daewoong Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Over the Counter Drugs | CDMO Service | Nabota |
| Prescription Drugs | Envlo | |
| Generics | CareTropin | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Others | In July, the company terminated the sale of CGBio Co to IMM Private Equity. |
| 2026 | Contracts/Agreements | In July, the company signed a consignment sales contract with Waysen to enter the AI endoscopy software market. |
| 2026 | Asset Purchase | In May, the company acquired Core Platform from Turn Biotechnologies. |
Competitor Comparison
| Key Parameters | Daewoong Pharmaceutical Co Ltd | Yuhan Corp | GC Biopharma Corp | Dong-A Socio Holdings Co Ltd | Huons Global Co Ltd |
|---|---|---|---|---|---|
| Headquarters | South Korea | South Korea | South Korea | South Korea | South Korea |
| City | Hwaseong | Seoul | Yongin-si | Seoul | Seongnam |
| No. of Employees | 1,742 | 1,594 | 2,355 | 273 | 541 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Seongsoo Park | Director; Chief Executive Officer | Executive Board | 2023 | - |
| Changjae Lee | Director; Chief Executive Officer | Executive Board | 2021 | - |
| Eunkyeong Park | Head - CH Marketing Division; Director | Executive Board | 2024 | - |
| In Hyuk Choi | Director | Non Executive Board | 2026 | - |
| Dae Hyun Choi | Director | Non Executive Board | 2026 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer